Fort Wayne Medical Oncology and Hematology (FWMOH) was pleased to welcome Dennis Slamon, M.D., a world-renowned breast cancer researcher, to its facilities on Thursday, October 22, 2015. Founder and head of Translational Research In Oncology (TRIO)-USA, Slamon’s purpose in visiting the Fort Wayne clinic is to assess its viability as a future partner in clinical trial research. In addition, Dr. Slamon presented a talk about the TRIO cancer research network to medical, radiation, and surgical oncologists from the greater Fort Wayne area.
“We are thrilled that Dr. Slamon has made the trip to Fort Wayne,” says Dr. Sunil Babu, director of research at FWMOH. “The proposed partnership will create much greater access to a wide array of clinical trials, giving our patients a chance to receive what is often cutting-edge treatment without the added stress of traveling to a large, metropolitan area.”
While FWMOH has a long and successful history of participating in clinical trials through pharmaceutical companies and the National Cancer Institute, the practice is looking forward to the possibility of adding the large portfolio of trials that TRIO brings to the table.
Fort Wayne Medical Oncology and Hematology provides state-of-the-art cancer and hematological (blood disorders) treatment through its team of dedicated physicians and health-care professionals. Since 1977, Fort Wayne Medical Oncology and Hematology has treated thousands of cancer patients in more than 40 areas of cancer, as well as patients with blood disorders. FWMOH is the only medical oncology group in northeast Indiana to obtain the highly acclaimed QOPI certification in 2014 and the Excellence in Clinical Research award during the annual meeting at American Society of Clinical Oncology in 2008. To learn more, visit fwmoh.com.
About Dennis Slamon, M.D., and TRIO
Dennis Slamon, M.D., is best known for his role in developing Herceptin, a highly successful treatment for breast cancer. TRIO is a not-for-profit clinical research organization dedicated to advancing translational cancer research by bringing forward innovative and targeted therapeutic concepts into the clinical trial setting. With a worldwide network of 2,000 investigators, TRIO has a proven track record of delivering clinical trial results accurately, efficiently, and on time. To learn more, visit cirg.org.